These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10191234)

  • 1. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors.
    Bradney AP; Scheer S; Crawford JM; Buchbinder SP; Montefiori DC
    J Infect Dis; 1999 May; 179(5):1264-7. PubMed ID: 10191234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H
    Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals.
    Kelly HR; Urbanski M; Burda S; Zhong P; Konings F; Nanfack J; Tongo M; Kinge T; Achkar J; Nyambi P
    Hum Antibodies; 2005; 14(3-4):89-99. PubMed ID: 16720979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy.
    Wang FX; Kimura T; Nishihara K; Yoshimura K; Koito A; Matsushita S
    J Infect Dis; 2002 Mar; 185(5):608-17. PubMed ID: 11865417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia.
    Günthard HF; Huber M; Kuster H; Shah C; Schüpbach J; Trkola A; Böni J
    Clin Infect Dis; 2009 Jun; 48(11):e117-20. PubMed ID: 19382874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
    Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
    Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection.
    Koning FA; Kwa D; Boeser-Nunnink B; Dekker J; Vingerhoed J; Hiemstra H; Schuitemaker H
    J Infect Dis; 2003 Sep; 188(6):864-72. PubMed ID: 12964118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity.
    Bunnik EM; Lobbrecht MS; van Nuenen AC; Schuitemaker H
    Virology; 2010 Feb; 397(1):224-30. PubMed ID: 19945135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virologic and host characteristics of human immunodeficiency virus type 1-infected pediatric long term survivors.
    Alexander L; Cuchura L; Simpson BJ; Andiman WA
    Pediatr Infect Dis J; 2006 Feb; 25(2):135-41. PubMed ID: 16462290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission.
    Lathey JL; Tsou J; Brinker K; Hsia K; Meyer WA; Spector SA
    J Infect Dis; 1999 Aug; 180(2):344-50. PubMed ID: 10395848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects.
    Cecilia D; Kleeberger C; Muñoz A; Giorgi JV; Zolla-Pazner S
    J Infect Dis; 1999 Jun; 179(6):1365-74. PubMed ID: 10228056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.
    Mahalanabis M; Jayaraman P; Miura T; Pereyra F; Chester EM; Richardson B; Walker B; Haigwood NL
    J Virol; 2009 Jan; 83(2):662-72. PubMed ID: 18987151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High level serum neutralizing antibody against HIV-1 in Chinese long-term non-progressors.
    Wang Q; Shang H; Han X; Zhang Z; Jiang Y; Wang Y; Dai D; Diao Y
    Microbiol Immunol; 2008 Apr; 52(4):209-15. PubMed ID: 18426395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection.
    Björling E; Scarlatti G; von Gegerfelt A; Albert J; Biberfeld G; Chiodi F; Norrby E; Fenyö EM
    Virology; 1993 Mar; 193(1):528-30. PubMed ID: 8438591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable biological and antigenic characteristics of HIV-2SBL6669 in nonpathogenic infection of macaques.
    Zhang YJ; Putkonen P; Albert J; Ohman P; Biberfeld G; Fenyö EM
    Virology; 1994 May; 200(2):583-9. PubMed ID: 7909969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
    Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
    J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment.
    Sarmati L; d'Ettorre G; Nicastri E; Ercoli L; Uccella I; Massetti P; Parisi SG; Vullo V; Andreoni M
    Clin Diagn Lab Immunol; 2001 Jul; 8(4):822-4. PubMed ID: 11427434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro.
    Quakkelaar ED; Bunnik EM; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Schuitemaker H
    Virology; 2007 Jul; 363(2):447-53. PubMed ID: 17355886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
    Derdeyn CA; Decker JM; Bibollet-Ruche F; Mokili JL; Muldoon M; Denham SA; Heil ML; Kasolo F; Musonda R; Hahn BH; Shaw GM; Korber BT; Allen S; Hunter E
    Science; 2004 Mar; 303(5666):2019-22. PubMed ID: 15044802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal quantification of human immunodeficiency virus type 1 DNA and RNA in long-term nonprogressors.
    Broström C; Visco-Comandini U; Yun Z; Sönnerborg A
    J Infect Dis; 1999 Jun; 179(6):1542-8. PubMed ID: 10228079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.